Acquisitions continued Acquisition of Putney The revised fair values of the acquired assets and liabilities on the acquisition of Putney are detailed below: Fair value 000 Recognised amounts of identifiable assets acquired and liabilities assumed Identifiable assets Property, plant and equipment 466 Inventories 14,037 Trade and other receivables 5,699 Cash and cash equivalents 1,541 Trade and other payables 7,160 Provisions 546 Debt 6,299 Identifiable intangible assets 112,580 Net deferred tax liability 31,517 Net identifiable assets 88,801 Goodwill 45,391 Total consideration 134,192 Satisfied by: Cash 134,192 Total consideration transferred 134,192 Net cash outflow arising on acquisition Cash consideration 134,192 Less cash and cash equivalents acquired 1,541 132,651 33.
Related Party Transactions Subsidiaries The Groups ultimate Parent Company is Dechra Pharmaceuticals PLC.
A listing of subsidiaries is shown within the financial statements of the Company on pages 167 to 168.
Transactions with Key Management Personnel The details of the remuneration, Long Term Incentive Plans, shareholdings, share options and pension entitlements of individual Directors are included in the Directors Remuneration Report on pages 81 to 101.
The remuneration of key management is disclosed in note 8.
Non-Controlling Interests Refer to note 27 for transactions with non-controlling interests during the year.
Off Balance Sheet Arrangements The Group has no off balance sheet arrangements to disclose as required by S410A of the Companies Act 2006.
Events after the Reporting Period On 25 July 2017, the Group signed a new Credit agreement refinancing its previous 205.0 million Revolving Credit Facility RCF.
The new committed facilities are a new five year multi-currency RCF with two one year extension options for 235.0 million through seven banks: HSBC, BNP Paribas, Fifth Third, Santander, Lloyds, Bank of Ireland and Raiffeisen.
The RCF has an Accordion facility of a further 125.0 million.
There are two covenants governing the RCF: Leverage: Net Debt to underlying EBITDA not greater than 3:1 Interest cover: underlying EBITDA to Net Finance Charges not less than 4:1 There is a non-utilisation fee of 35.0% of the applicable margin.
The margin over LIBOR or equivalent ranges from 1.3% for gearing below 1 time, up to 2.2% for gearing above 2.5 times.
Following the refinancing, the existing capitalised arrangement fees of 0.4 million will be accelerated to the income statement.
Stock Code: DPH 159 slugline Dechra Annual Report 2017 - Back.
indd 159 04 09 2017 14:01:12 Company Statement of Financial Position At 30 June 2017 2017 2016 Note 000 000 Non-current assets Investments iv 447,489 413,199 Intangible assets v 7,715 5,726 Tangible assets vi 122 197 455,326 419,122 Current assets Trade and other receivables includes amounts falling due after more than one year of 1,362,000 2016: 1,351,000 vii 15,129 18,617 Cash at bank and in hand 15,129 18,617 Borrowings ix 11,334 32,133 Trade and other payables viii 66,073 34,745 Net current liabilities 62,278 48,261 Total assets less current liabilities 393,048 370,861 Non-current liabilities Borrowings ix 151,793 128,163 Net assets 241,255 242,698 Equity Called up share capital xi 932 927 Share premium account 173,376 172,451 Foreign currency translation reserve 545 545 Hedging reserve 15 At 1 July 68,790 86,768 Profit loss for the year attributable to the owners 11,829 5,772 Other changes in retained earnings 14,217 12,206 Retained earnings 66,402 68,790 Total equity shareholders funds 241,255 242,698 The financial statements were approved by the Board of Directors on 4 September 2017 and are signed on its behalf by: Ian Page Richard Cotton Chief Executive Officer Chief Financial Officer 4 September 2017 4 September 2017 Company number: 3369634 160 Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2017 www.
com slugline Dechra Annual Report 2017 - Back.
